HilleVax, Inc. (NASDAQ:HLVX – Get Rating) – Investment analysts at SVB Leerink boosted their Q2 2023 earnings per share (EPS) estimates for shares of HilleVax in a research note issued on Monday, May 15th. SVB Leerink analyst D. Risinger now anticipates that the company will post earnings of ($0.88) per share for the quarter, up from their previous estimate of ($1.00). The consensus estimate for HilleVax’s current full-year earnings is ($4.63) per share. SVB Leerink also issued estimates for HilleVax’s Q3 2023 earnings at ($1.00) EPS, Q4 2023 earnings at ($1.31) EPS, FY2023 earnings at ($3.90) EPS, Q1 2024 earnings at ($1.09) EPS, Q2 2024 earnings at ($0.87) EPS, Q3 2024 earnings at ($0.66) EPS, Q4 2024 earnings at ($0.65) EPS, FY2024 earnings at ($3.20) EPS, FY2025 earnings at ($2.79) EPS, FY2026 earnings at ($2.27) EPS and FY2027 earnings at ($1.19) EPS.
HilleVax (NASDAQ:HLVX – Get Rating) last posted its earnings results on Friday, March 17th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.42.
HilleVax Price Performance
Hedge Funds Weigh In On HilleVax
Several institutional investors and hedge funds have recently modified their holdings of HLVX. Russell Investments Group Ltd. acquired a new position in shares of HilleVax in the 1st quarter valued at approximately $26,000. UBS Group AG grew its position in shares of HilleVax by 9,300.0% in the 4th quarter. UBS Group AG now owns 1,692 shares of the company’s stock valued at $28,000 after purchasing an additional 1,674 shares during the period. Shell Asset Management Co. acquired a new position in shares of HilleVax in the 4th quarter valued at approximately $41,000. Tower Research Capital LLC TRC boosted its position in HilleVax by 57.4% during the 1st quarter. Tower Research Capital LLC TRC now owns 2,587 shares of the company’s stock worth $43,000 after acquiring an additional 943 shares during the last quarter. Finally, Gyon Technologies Capital Management LP acquired a new position in HilleVax during the 4th quarter worth approximately $53,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.
HilleVax Company Profile
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
- Get a free copy of the StockNews.com research report on HilleVax (HLVX)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.